Efficacy of myocardial protection by nicorandil during open-heart surgery under cardiopulmonary bypass

Efficacy of myocardial protection by nicorandil during open-heart surgery under cardiopulmonary bypass - Myocardial protection by nicorandil

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005260

Enrollment

Registered

2011-04-01

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

valvular heart disease

Interventions

aortic valve surgery transvenous administration of nicorandil (6mg/hr) for 24 hours. aortic valve surgery control cardiac valve surgery(except aortic valve), transvenous administration of nico

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: elective heart valve replacement or plasty surgery

Exclusion criteria

Exclusion criteria: emergency surgery

Design outcomes

Primary

Measure	Time frame
Hemodynamics, markers for myocardial damage(CK-MB,TnT,H-FABP etc) at five time points(anesthesia induction, just, 1hr, 5hr and 24hr after cardiopulmonary bypass stopped).	—

Countries

Japan

Contacts

Public ContactSachiko Jomura

Kansai Medical University Hirakata hospital Dept. Anesthesiology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026